When Supplement Brands Become Corporate Assets: What P&G’s $3.8 Billion Thorne Deal Says About Consolidation in Natural Health

On August 4, 2026, Procter & Gamble agreed to acquire Thorne for $3.8 billion in cash, giving one of the world’s largest consumer-products companies a much larger position in the supplement market [1]. Thorne is expected to generate roughly $650 million in sales this year and will join a P&G health portfolio that already includes brands such as New Chapter, Metamucil, and Align Probiotic [1]. 

The purchase price is particularly striking when compared with Thorne’s recent history. Private-equity firm L Catterton acquired Thorne in 2023 in a transaction valued at approximately $680 million [2]. Less than three years later, P&G agreed to pay $3.8 billion for the company [1]. Thorne unquestionably grew during that period, but the enormous increase in transaction value also shows how highly major corporations now value the supplement and wellness market.

The concern is what happens when acquisitions like this become part of a larger industry trend in which fewer companies ultimately control more of the brands consumers see on store shelves. This phenomenon is sometimes described as the “illusion of choice,” and it is already familiar in other parts of the grocery store. A cereal aisle may contain scores of boxes with different names, mascots, flavors, and marketing claims, while a large share of those products ultimately belongs to only a handful of parent companies: Kellogg, General Mills, and Post. The consumer appears to be choosing among dozens of competitors, even though considerably fewer companies are actually making the decisions behind those brands.

When these companies purchase smaller brands and fold them into much larger portfolios, the qualities that originally distinguished those brands can become secondary to scale, margins, manufacturing efficiency, and the priorities of the parent company. Similar consolidation has occurred throughout the natural-food market, including PepsiCo’s acquisition of Siete Foods in 2025 and General Mills’ acquisition of Annie’s in 2014.

Natural Health Has Become a Major Corporate Growth Market

Thorne is not a struggling company being rescued. It is an established supplement company with a reputation for clinical positioning, specialized formulas, practitioner relationships, and research. That is precisely what makes the acquisition significant.

P&G reported $87 billion in net sales for fiscal 2026, while sales increased only 1% [3]. Against that backdrop, health and wellness offers an attractive area for expansion. Reuters reported that P&G views the acquisition as part of its push into self-care, prevention, wellness, and personalized health, areas where consumer interest continues to grow [1][3]. 

Other large consumer companies have recognized the same opportunity. Unilever has expanded in supplements and wellness, Nestlé has a substantial nutrition business, and Thorne reportedly attracted interest from several large strategic buyers before P&G prevailed [1]. The supplement market that was once dominated by smaller vitamin companies and health-food businesses is increasingly attracting companies accustomed to operating global consumer brands.

More Brands Do Not Always Mean More Competition

Just like a trip through the food aisles, a walk through the supplement section of a store may appear to have almost unlimited choice. Bottles have different labels, different marketing language, different target customers, and different price points.

A market can have dozens of brands while a much smaller number of parent companies own them. When that happens, consumers still see many labels, but there are fewer truly independent businesses deciding what ingredients to use, what doses to offer, what products to develop, and how aggressively to compete on price.

Federal antitrust agencies recognize that competition is not limited to price. Companies compete by offering better products, new features, greater variety, improved quality, and new research and development [4]. When formerly independent competitors come under common ownership, some of that independent competitive pressure disappears [4].

For supplements, where small differences in formulation can matter substantially, ownership diversity has particular value.

What Happens to Specialized Formulas?

One reason people become loyal to certain supplement companies is that those companies are willing to make products that do not necessarily appeal to everyone.

For instance, a specialized company might use a more expensive patented ingredient because it believes the absorption data are stronger. Or, it might offer an unusually high or low dosage because a particular group of customers wants it. It might also keep a niche product in the catalog despite modest sales because practitioners continue to use it. It may even introduce an obscure nutrient years before the general public has heard of it.

On the contrary, a multinational consumer company evaluates products within a much larger organization. Manufacturing efficiency, inventory turnover, supply-chain simplicity, margins, marketing potential, and the ability to sell a product at scale naturally become part of the equation.

Thus, the incentives are different once a specialized supplement brand becomes one part of an $87 billion corporation [3]. A product that makes perfect sense within a dedicated supplement company may look less attractive if it uses an expensive raw material, sells to a relatively small audience, complicates manufacturing, or competes with another product elsewhere in a large corporate portfolio.

Consumers who care about formulation should therefore pay attention not only to a brand name but to what happens to the actual products over time.

Consolidation Can Affect Innovation

Although large companies can spend much more money on research than most independent supplement businesses, another type of innovation often comes from smaller companies.

Small supplement brands can afford to pursue ideas that are too narrow to interest a multinational company. An emerging ingredient does not initially need to become a $100 million product. A small business can introduce it because the research looks interesting and a few thousand customers want it.

The Department of Justice and Federal Trade Commission specifically recognize product variety and innovation as forms of competition. Their merger guidelines note that independent competitors may have stronger incentives to introduce new products or improve existing ones because they are trying to take business from each other. Once companies share ownership, a new product may instead take sales from another product owned by the same parent company [4].

That issue is especially relevant to supplements because the industry changes quickly. Ingredients such as methylfolate, tocotrienols, magnesium L-threonate, specialized collagen peptides, ubiquinol, geranylgeraniol, and dihydroberberine all began as relatively specialized products before receiving broader consumer attention.

Large Buyers Gain More Power Over Suppliers

Consolidation can also affect companies that consumers never see that work in the background and in supply chains.

Supplement manufacturers buy vitamins, minerals, herbal extracts, patented ingredients, capsules, oils, packaging, laboratory testing, and manufacturing services. If a growing share of the industry’s sales is controlled by a smaller number of enormous buyers, those companies gain leverage when negotiating with suppliers.

Some of this is beneficial. Large orders can lower manufacturing costs, and those savings may ultimately reach consumers.

However, too much buyer concentration can create the opposite problem. Federal antitrust guidelines recognize that when competition among buyers declines, suppliers may receive lower prices or fewer purchase opportunities, which can reduce their incentive to invest in new capacity or innovation [5].

That is relevant in natural health because many interesting raw materials come from smaller specialty ingredient companies. A patented extract or newly developed nutrient may require years of research before it becomes commercially viable. Those companies need enough customers, and enough bargaining power, to justify that investment.

If a small number of enormous supplement companies increasingly determine which ingredients reach mass-market consumers, they can also gain considerable influence over which innovations survive or even stifle certain innovations altogether.

The Private-Equity and Institutional Investor Side of the Story

Thorne’s path from public company to private-equity ownership and now to P&G also illustrates how supplement brands have become financial assets.

L Catterton agreed to acquire Thorne for approximately $680 million in 2023, paying a substantial premium to its prior stock price [2]. The firm took Thorne private, and less than three years later, P&G agreed to buy it for $3.8 billion [1][2].

Currently, Yahoo Finance shows that BlackRock, Vanguard, and State Street own an 8.17%, 6.50%, and 4.40% interest, respectively, in P&G, meaning nearly 20% of P&G is owned by three Wall Street Institutional Holders. In total, Institutional Holders own about 70% of P&G.

Consequentially, P&G ultimately answers to a vast network of shareholders and institutional investors, while an independent company can remain much closer to the customers actually purchasing and using its products.

Why Small, Independent Companies Like Healthmasters Are Necessary

For small, family-run, independent companies such as Healthmasters, this P&G purchase underlines why independence still matters.

A smaller supplement company cannot outspend P&G on advertising or match its worldwide distribution network. Still, Healthmasters can compete in a different way: by remaining focused on formulation, emerging research, specialized nutrients, and customers who pay close attention to what is actually inside the bottle.

Just as importantly, Healthmasters maintains a direct relationship with its customers. Someone with a question about an ingredient, dosage, or product can call and speak directly with a representative familiar with the company’s supplements. That kind of individual interaction is much easier to preserve in a focused, independent business than inside a corporation managing hundreds of products across dozens of consumer categories.

Conclusion

P&G paying $3.8 billion for Thorne is another sign that natural health has moved firmly into the corporate mainstream [1]. Some major questions remain: Do the formulations remain the same? Are ingredient forms or dosages changed? Are niche products discontinued? Does quality testing improve? Does P&G fund larger clinical trials? Do prices rise or fall? Does Thorne maintain its practitioner-oriented approach, or does it gradually become a more conventional mass-market wellness brand?

Nevertheless, at Healthmasters, we will remain focused on what independent supplement companies can still do particularly well: use top-tier ingredients, investigate niche and emerging compounds, maintain specialized formulas, and provide customers with direct, one-on-one service. As more supplement companies become pieces of much larger corporate portfolios, preserving that independence becomes part of what distinguishes Healthmasters in the first place.

References

[1] Reuters. (2026, August 4). P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies.

[2] Thorne HealthTech, Inc. (2023, August 28). Thorne HealthTech, Inc. enters into definitive agreement to be acquired by L Catterton for $10.20 per share in cash.

[3] The Procter & Gamble Company. (2026, July 29). P&G announces fourth quarter and fiscal year 2026 results.

[4] U.S. Department of Justice & Federal Trade Commission. (2023). 2023 merger guidelines: Evaluating competition among firms.

[5] U.S. Department of Justice & Federal Trade Commission. (2023). 2023 merger guidelines: Guideline 10: When a merger involves competing buyers.